Mice passively immunized prior to a challenge infection with immunoglobulin G (IgG) and IgM monoclonal antibodies (MAbs) specific for a common epitope of both A-and M-dominant strains had viable Brucella abortus 544 or Brucella melitensis H38 counts in the spleen reduced to the same extent as did mice passively immunized with MAbs specific for either the A or the M epitope. The IgA MAb was not effective.
The smooth lipopolysaccharide (S-LPS) of smooth Brucella spp. has been found to contain two distinct epitopes designated A and M (2, 3, 5, 6, 9, 12) . The relative amounts of the two epitopes vary among smooth Brucella strains, and these epitopes are absent on rough Brucella strains (1) .
Monoclonal antibodies (MAbs) to S-LPS were previously shown to confer protection in mice by reducing the number of Brucella cells in the spleen and liver (7, 8, 10, 11) . By using an anti-A, anti-M MAb, Limet et al. (7, 8) have demonstrated the importance of MAb specificity in conferring protection against challenge strains expressing mostly one or the other S-LPS epitope. We obtained MAbs of different isotypes and directed against a common epitope shared by A and M S-LPSs by fusion with NSO myeloma cells of spleen cells from mice infected with rough Brucella melitensis B115 (4). Our purpose was to evaluate in BALB/c mice the protective activity of these MAbs, characterized by immunoblotting and enzyme-linked immunosorbent assay (ELISA), against a B. melitensis or Brucella abortus virulent challenge strain expressing, respectively, the M or A epitope as the dominant S-LPS epitope and to compare their activity with that of MAbs specific for either the A or the M epitope (7) .
In immunoblotting with two S-LPSs, i.e., S-LPS A of B. abortus 99 and S-LPS M of B. melitensis 16M, immunoglobulin G2a (IgG2a) MAb 04F9 (MAb-A) revealed only S-LPS A, IgG3 MAb 2E11 (MAb-M) revealed only S-LPS M, and IgGl MAb 12G12 revealed both S-LPSs equally well (Fig. 1) . IgA MAb 18H08 and IgM MAb 13G11 also revealed both S-LPSs (data not shown). In ELISA the three MAbs specific for the common epitope bound equally well to S-LPS from reference strains of B. abortus (99), B. melitensis (16M), and Brucella suis (biovar 4) (data not shown). The S-LPS structure has been defined as homopolymers of 4,6-dideoxy-4-formamido-ox-D-mannopyranose residues. S-LPS A is a linear, a-1,2-linked polymer with about 2% oa-1,3-linkages, while S-LPS M is a linear polymer of pentasaccharide repeating units containing one a-1,3-linked and four a-1,2-linked monosaccharide residues (2, 3, 9) . Apparently, the a-1,3 linkage is the major part of the structure recognized by * Corresponding author.
MAb-M. The percentage of a-1,3 linkages correlates with the reactivity of MAb-M with S-LPSs of B. abortus, B. melitensis, and B. suis expressing the M epitope in variable amounts (9; unpublished results). However, the structure recognized by MAbs specific for the epitope A and the common epitope has yet to be determined. Such a determination should be possible with synthetic oligosaccharides as described by Bundle et al. (2) .
In ELISA MAb-M bound to B. melitensis H38 (M-dominant) cells at a high dilution but not to B. abortus 544 (A-dominant) cells (Fig. 2) . One or two a-1,3 linkages occur per LPS chain in A-dominant strains (2). The very low binding of MAb-M to the A-dominant strain (105-to 106-fold lower than that to the M-dominant strain) could be explained by the fact that all a-1,3 linkages are not accessible to MAb-M on S-LPS A at the cell surface. MAb-A bound to both strains but had a 100-fold lower titer against B. melitensis H38. S-LPS MAbs 12G12, 13G11, and 18H08 bound equally well to both strains. In a previous study with the same MAb-A and MAb-M, MAb-A conferred significant protection against B. melitensis H38 only at day 7 postchallenge (7). The injected dose of MAb-A was, however, very weak (4 ,ug) , and the titer against B. melitensis H38 was very low (1/30 7 days postchallenge (7). The mice used for that experiment were, however, CD-1 mice, which are less sensitive to B. abortus 544 infection than the BALB/c mice used in this study, as indicated by the fact that a decrease (>1 log) in the number of Brucella cells in the spleen was already observed in control CD-1 mice at 21 days postchallenge. Therefore, to evaluate long-term protection against B. abortus 544, mice such as BALB/c mice seem to be more appropriate, since chronic infection can be established more easily.
The binding of MAbs to challenge strains seems to be requisite for good protection, but the degree of protection conferred is not directly related to the antibody titer against the challenge strains. Indeed, although better binding (higher titer) of MAb-M than of MAb-A was observed with B. melitensis H38 cells, MAb-A conferred better protection than did MAb-M against this strain at 7, 21, and 49 days postchallenge. This result could be explained by the fact that protection depends on the ability of the antibody to improve bacterial clearance. This phenomenon depends on both the ability of the antibody to bind bacteria and the ability of macrophage receptors to capture the opsonized bacteria. The functional affinity of the antibody and the abundance and accessibility of the A epitope on the challenge strain influence the first step, and the antibody subclass influences the second step. a-1,2-Linkages are probably involved in the structure of the A epitope, and the number of a-1,2-linkages always exceeds the number of a-1,3-linkages in the M-dominant strain. However, in the present case, the accessibility of the A epitope to the antibody is a prerequisite but is probably not the limiting factor, and it is worth noting that the functional affinity rather than the intrinsic affinity or avidity is the most important factor affecting binding in vivo and subsequent protection. Our results suggest that mainly IgG but also IgM antibodies against the common epitope of Brucella S-LPSs are efficient against the two Brucella species tested, which express the A and M epitopes in variable amounts. Therefore, vaccine development could be based on the common epitope and not only on either the A or the M epitope as suggested previously (7).
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